Investigators behind the SELECT trial have published new analyses exploring the relationship between weight loss and cardiovascular outcomes from semaglutide. The authors addressed critiques about whether changes in adiposity merely signal or actually cause the drug's protective effect against major adverse cardiac events.
To distinguish between weight change as a marker versus a mechanism, the team employed three analytical strategies. These included a primary landscape analysis, a time-varying covariate model that accounts for temporal sequencing, and supplementary assessments of cumulative weight loss at a fixed point regardless of whether it preceded or followed an event.
The correspondence responds directly to concerns raised by Justin Tondt and Vernon M Chinchilli. The authors make clear their approach was designed to evaluate evidence for weight reduction acting as either a prognostic indicator or a direct mediator of semaglutide's cardiovascular benefits.
These findings carry implications for understanding how GLP-1 receptor agonists protect the heart. If weight loss is merely a marker, other mechanisms—such as anti-inflammatory effects—may be more central, potentially shifting how physicians prioritize treatment benefits.
Experts caution that post-hoc analyses, however rigorous, cannot definitively prove causation. The authors acknowledge their work does not resolve the marker-versus-mechanism debate but provides a framework for future study.